J Korean Surg Soc.  2011 Dec;81(6):394-401. 10.4174/jkss.2011.81.6.394.

Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma

• Yoon KW
• Heo JS
• Choi DW
• Choi SH

• KMID: 1445768
• DOI: http://doi.org/10.4174/jkss.2011.81.6.394

Abstract

PURPOSE
Some patients who undergo surgical resection of pancreatic cancer survive longer than other patients. The purpose of this study was to identify the factors that affect long-term survival after resection of histopathologically confirmed pancreatic ductal adenocarcinoma.
METHODS
A single-center, retrospective study was conducted among 164 patients who underwent surgical resection of pancreatic cancer, between May 1995 and December 2004. The patient follow-up process was conducted via telephone survey and review of electronic medical records for at least 5 years or until death.
RESULTS
We compared patients with long-term (> or =60 months, n = 19) and short-term survival (<60 months, n = 145). Resection margin status, differentiation of the tumor, tumor stage, pre-operative serum level of albumin, total bilirubin and carbohydrate antigen (CA) 19-9 level are related with survival difference (all factors, P < 0.05). Multivariate analysis revealed that a pre-operative serum total bilirubin level <7 mg/dL and a pre-operative serum CA19-9 level <37 U/mL is a statistically significant prognostic factor for long-term survival.
CONCLUSION
The preoperative serum total bilirubin and serum CA19-9 levels are associated with long-term survival after surgical resection of pancreatic cancer.

Keyword

Pancreatic neoplasms; Bilirubin; CA19-9 antigen

MeSH Terms

Adenocarcinoma
Bilirubin
Electronic Health Records
Follow-Up Studies
Humans
Multivariate Analysis
Pancreatic Ducts
Pancreatic Neoplasms
Retrospective Studies
Telephone
Bilirubin

Figure

• 

  Fig. 1 Survival in 164 patients after surgical resection of pancreatic ductal adenocarcinoma. (A) Overall survival. (B) Survival dependent on preoperative serum total bilirubin level (<7 mg/dL vs. ≥7 mg/dL; log-rank test, P = 0.002). (C) Survival dependent on preoperative serum carbohydrate antigen (CA) 19-9 level (<37 U/mL vs. ≥37 U/mL; log-rank test, P < 0.001).

Reference

1. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010. 25:1113–1121.

2. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003. 27:324–329.

3. Krejs GJ. Pancreatic cancer: epidemiology and risk factors. Dig Dis. 2010. 28:355–358.

4. Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, Hruban RH, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6-to 10-year follow-up. Surgery. 2006. 140:764–772.

5. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, et al. Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma. J Gastrointest Surg. 2008. 12:534–541.

6. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008. 247:456–462.

7. Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas. 2006. 32:271–275.

8. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006. 10:1199–1210.

9. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006. 260:103–117.

10. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004. 198:722–731.

11. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 1991. 161:120–124.

12. Choi SB, Park SW, Kim KS, Choi JS, Lee WJ. The survival outcome and prognostic factors for middle and distal bile duct cancer following surgical resection. J Surg Oncol. 2009. 99:335–342.

13. Ong SL, Garcea G, Thomasset SC, Mann CD, Neal CP, Abu Amara M, et al. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg. 2008. 12:1068–1073.

14. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004. 350:1200–1210.

15. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA. 2001. 286:921–929.

16. Benassai G, Mastrorilli M, Mosella F, Mosella G. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res. 1999. 18:23–28.

17. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993. 165:68–72.

18. Takahashi T, Niino N, Ishikura H, Okushiba S, Dohke M, Katoh H. Predictive factors for long-term survival in patients with pancreatic carcinoma. Hepatogastroenterology. 1997. 44:1463–1468.

19. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000. 4:567–579.

20. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003. 237:74–85.

21. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004. 11:644–649.

22. Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005. 92:1372–1381.

23. Moon HJ, An JY, Heo JS, Choi SH, Joh JW, Kim YI. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas. 2006. 32:37–43.

24. Ouaissi M, Sielezneff I, Pirro N, Merad A, Loundou A, Chaix JB, et al. Pancreatic cancer and pancreaticoduodenectomy in elderly patient: morbidity and mortality are increased. Is it the real life? Hepatogastroenterology. 2008. 55:2242–2246.

25. Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K, et al. Prognostic factors after esection of pancreatic cancer. World J Surg. 2009. 33:104–110.

26. Smith RA, Dajani K, Dodd S, Whelan P, Raraty M, Sutton R, et al. Preoperative resolution of jaundice following biliary stenting predicts more favourable early survival in resected pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2008. 15:3138–3146.

27. Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitano S. Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas. 2005. 31:69–73.

28. Mukaiya M, Hirata K, Satoh T, Kimura M, Yamashiro K, Ura H, et al. Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan. World J Surg. 1998. 22:248–252.

29. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, et al. Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol. 2006. 93:485–490.

30. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987. 47:5501–5503.